Drugs / GD2Bi-aATC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02173093 | Nov 2014 → Dec 2019 | neuroblastoma | University of Virginia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2Bi-aATC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02173093 ↗ |
| Modality | Cell therapy | “The investigators put the GD2 bispecific antibody on T cells and give large numbers of these T cells back to patients.” NCT02173093 ↗ |
| Route | Intravenous | “Given IV” NCT02173093 ↗ |